| 1 |
Jorfi M, Maaser-Hecker A, Tanzi RE. The neuroimmune axis of Alzheimer's disease[J]. Genome Med, 2023, 15(1):6. doi: 10.1186/s13073-023-01155-w.
|
| 2 |
Zhang Y, Chen H, Li R, et al. Amyloid β-based therapy for Alzheimer's disease:challenges, successes and future[J]. Signal Transduct Target Ther, 2023, 8(1):248. doi: 10.1038/s41392-023-01484-7.
|
| 3 |
Zhang H, Wei W, Zhao M, et al. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease[J]. Int J Biol Sci, 2021, 17(9):2181-2192.
|
| 4 |
Xiong W, Liu Y, Zhou H, et al. Alzheimer's disease: pathophysiology and dental pulp stem cells therapeutic prospects[J]. Front Cell Dev Biol, 2022, 10:999024. doi: 10.3389/fcell.2022.999024.
|
| 5 |
Dewanjee S, Chakraborty P, Bhattacharya H, et al. Altered glucose metabolism in Alzheimer's disease: role of mitochondrial dysfunction and oxidative stress[J]. Free Radic Biol Med, 2022, 193(Pt 1):134-157.
|
| 6 |
Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease[J]. Nat Rev Neurosci, 2019, 20(3):148-160.
|
| 7 |
Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer's disease[J]. Biomed Rep, 2016, 4(5):519-522.
|
| 8 |
Park MW, Cha HW, Kim J, et al. NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases[J]. Redox Biol, 2021, 41:101947. doi: 10.1016/j.redox.2021.101947.
|
| 9 |
Andrzejewska A, Dabrowska S, Lukomska B, et al. Mesenchymal stem cells for neurological disorders[J]. Adv Sci (Weinh), 2021, 8(7):2002944. doi: 10.1002/advs.202002944.
|
| 10 |
Sivandzade F, Cucullo L. Regenerative stem cell therapy for neurodegenerative diseases: an overview[J]. Int J Mol Sci, 2021, 22(4): 2153. doi: 10.3390/ijms22042153.
|
| 11 |
Jia Y, Cao N, Zhai J, et al. HGF mediates clinical-grade human umbilical cord-derived mesenchymal stem cells improved functional recovery in a senescence-accelerated mouse model of Alzheimer's disease[J]. Adv Sci (Weinh), 2020, 7(17):1903809. doi: 10.1002/advs.201903809.
|
| 12 |
Santamaria G, Brandi E, Vitola P, et al. Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice[J]. Cell Death Differ, 2021, 28(1):203-218.
|
| 13 |
Zhang XM, Ouyang YJ, Yu BQ, et al. Therapeutic potential of dental pulp stem cell transplantation in a rat model of Alzheimer's disease[J]. Neural Regen Res, 2021, 16(5):893-898.
|
| 14 |
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission[J]. Lancet, 2020, 396(10248):413-446.
|
| 15 |
Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study[J]. BMJ, 2017, 358: j2856. doi: 10.1136/bmj.j2856.
|
| 16 |
Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer's disease[J]. Alzheimers Dement, 2007, 3(3):186-191.
|
| 17 |
Leone M, Kuja-Halkola R, Leval A, et al. Association of youth depression with subsequent somatic diseases and premature death[J]. JAMA Psychiatry, 2021, 78(3):302-310.
|
| 18 |
Ben Hassen C, Fayosse A, Landré B, et al. Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall Ⅱ prospective cohort study[J]. BMJ, 2022, 376:e068005. doi: 10.1136/bmj-2021-068005.
|
| 19 |
Sabia S, Singh-Manoux A. Healthy lifestyles for dementia prevention[J]. BMJ, 2023, 380:117. doi: 10.1136/bmj.p117.
|
| 20 |
Lisko I, Kulmala J, Annetorp M, et al. How can dementia and disability be prevented in older adults: where are we today and where are we going?[J]. J Intern Med, 2021, 289(6):807-830.
|
| 21 |
Bian Y, Chen Y, Wang X, et al. Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer's disease[J]. J Adv Res, 2021, 34:1-12.
|
| 22 |
Harman D. Aging: a theory based on free radical and radiation chemistry[J]. J Gerontol, 1956, 11(3):298-300.
|
| 23 |
Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain[J]. Front Aging Neurosci. 2010, 2:12. doi: 10.3389/fnagi.2010.00012.
|
| 24 |
Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view[J]. Oxid Med Cell Longev, 2019, 2019:2105607. doi: 10.1155/2019/2105607.
|
| 25 |
Mecocci P, Boccardi V, Cecchetti R, et al. A long journey into aging, brain aging, and Alzheimer's disease following the oxidative stress tracks[J]. J Alzheimers Dis, 2018, 62(3):1319-1335.
|
| 26 |
Jomova K, Vondrakova D, Lawson M, et al. Metals, oxidative stress and neurodegenerative disorders[J]. Mol Cell Biochem, 2010, 345(1- 2): 91-104.
|
| 27 |
Fukuyama R, Nakayama A, Nakase T, et al. A newly established neuronal rho-0 cell line highly susceptible to oxidative stress accumulates iron and other metals. Relevance to the origin of metal ion deposits in brains with neurodegenerative disorders[J]. J Biol Chem, 2002, 277(44):41455-41462.
|
| 28 |
Han Y, Gao C, Wang H, et al. Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice[J]. Bioact Mater, 2021, 6(2):529-542.
|
| 29 |
Jomova K, Raptova R, Alomar SY, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants:chronic diseases and aging[J]. Arch Toxicol, 2023, 97(10):2499-2574.
|
| 30 |
Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration[J]. FEBS Lett, 2018, 592(5): 692-702.
|
| 31 |
Han S, Zhang M, Jeong YY, et al. The role of mitophagy in the regulation of mitochondrial energetic status in neurons[J]. Autophagy. 2021, 17(12):4182-4201.
|
| 32 |
Bahn G, Park JS, Yun UJ, et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models[J]. Proc Natl Acad Sci U S A, 2019, 116(25):12516-12523.
|
| 33 |
Liao S, Wu J, Liu R, et al. A novel compound DBZ ameliorates neuroinflammation in LPS-stimulated microglia and ischemic stroke rats: Role of Akt(Ser473)/GSK3β(Ser9)-mediated Nrf2 activation[J]. Redox Biol, 2020, 36:101644. doi: 10.1016/j.redox.2020.101644.
|
| 34 |
Dinkova-Kostova AT, Copple IM. Advances and challenges in therapeutic targeting of NRF2[J]. rends Pharmacol Sci, 2023, 44(3): 137-149.
|
| 35 |
Osama A, Zhang J, Yao J, et al. Nrf2: a dark horse in Alzheimer's disease treatment[J]. Ageing Res Rev, 2020, 64:101206. doi: 10.1016/j.arr.2020.101206.
|
| 36 |
Fragoulis A, Siegl S, Fendt M, et al. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease[J]. Redox Biol, 2017, 12:843-853.
|
| 37 |
Cheng L, Zhang W. DJ-1 affects oxidative stress and pyroptosis in hippocampal neurons of Alzheimer's disease mouse model by regulating the Nrf2 pathway[J]. Exp Ther Med, 2021, 21(6):557. doi: 10.3892/etm.2021.9989.
|
| 38 |
She L, Xiong L, Li L, et al. Ginsenoside Rk3 ameliorates Aβ-induced neurotoxicity in APP/PS1 model mice via AMPK signaling pathway[J]. Biomed Pharmacother, 2023, 158:114192. doi: 10.1016/j.biopha.2022.114192.
|
| 39 |
Ren J, Zhang S, Wang X, et al. MEF2C ameliorates learning, memory, and molecular pathological changes in Alzheimer’s disease in vivo and in vitro[J]. Acta Biochim Biophys Sin (Shanghai), 2022, 54(1):77-90.
|
| 40 |
Wu YH, Hsieh HL. Roles of heme oxygenase-1 in neuroinflammation and brain disorders[J]. Antioxidants (Basel). 2022, 11(5):923. doi: 10.3390/antiox11050923.
|
| 41 |
Barone E, Di Domenico F, Sultana R, et al. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment[J]. Free Radic Biol Med, 2012, 52(11-12):2292-2301.
|
| 42 |
Cao K, Xiang J, Dong YT, et al. Activation of α7 nicotinic acetylcholine receptor by its selective agonist improved learning and memory of amyloid precursor protein/presenilin 1 (APP/PS1) mice via the Nrf2/HO-1 pathway[J]. Med Sci Monit, 2022, 28:e933978. doi: 10.12659/MSM.933978.
|
| 43 |
Tarafdar A, Pula G. The role of NADPH oxidases and oxidative stress in neurodegenerative disorders[J]. Int J Mol Sci, 2018, 19(12):3824. doi: 10.3390/ijms19123824.
|
| 44 |
Tao W, Yu L, Shu S, et al. miR-204-3p/Nox4 mediates memory deficits in a mouse model of Alzheimer's disease[J]. Mol Ther, 2021, 29(1):396-408.
|
| 45 |
Malkov A, Popova I, Ivanov A, et al. Aβ initiates brain hypometabolism, network dysfunction and behavioral abnormalities via NOX2-induced oxidative stress in mice[J]. Commun Biol, 2021, 4(1):1054. doi: 10.1038/s42003-021-02551-x.
|
| 46 |
Nguyen TPN, Kumar M, Fedele E, et al. MicroRNA alteration, application as biomarkers, and therapeutic approaches in neurodegenerative diseases[J]. Int J Mol Sci, 2022, 23(9):4718. doi: 10.3390/ijms23094718.
|
| 47 |
Liu S, Fan M, Zheng Q, et al. MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets[J]. Biomed Pharmacother, 2022, 148:112681. doi: 10.1016/j.biopha.2022.112681.
|
| 48 |
Meng S, Wang B, Li W. CircAXL knockdown alleviates Aβ(1-42)-induced neurotoxicity in Alzheimer's disease via repressing PDE4A by releasing miR-1306-5p[J]. Neurochem Res, 2022, 47(6):1707-1720.
|
| 49 |
Duan W, Chen X. Jatrorrhizine can improve nerve cell injury induced by Aβ 25-35, acting through miR-223-3p/HDAC4 axis[J]. Am J Transl Res, 2021, 13(5):4644-4655.
|
| 50 |
Zhang YY, Bao HL, Dong LX, et al. Silenced lncRNA H19 and up- regulated microRNA-129 accelerates viability and restrains apoptosis of PC12 cells induced by Aβ(25-35) in a cellular model of Alzheimer's disease[J]. Cell cycle, 2021, 20(1):112-125.
|
| 51 |
Li S, Wu L, Ma M, et al. MicroRNA-668-3p regulates oxidative stress and cell damage induced by Aβ1-42 by targeting the OXR1/p53-p21 axis[J]. Ann Transl Med, 2022, 10(17):928. doi: 10.21037/atm-22-3598.
|
| 52 |
Lei B, Liu J, Yao Z, et al. NF-κB-induced upregulation of miR-146a- 5p promoted hippocampal neuronal oxidative stress and pyroptosis via TIGAR in a model of Alzheimer's disease[J]. Front Cell Neurosci, 2021, 15:653881. doi: 10.3389/fncel.2021.653881.
|
| 53 |
Azman KF, Zakaria R. Recent advances on the role of brain-derived neurotrophic factor (BDNF) in neurodegenerative diseases[J]. Int J Mol Sci, 2022, 23(12):6827. doi: 10.3390/ijms23126827.
|
| 54 |
Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease[J]. Nat Med, 2009, 15(3):331-337.
|
| 55 |
Kang T, Qu Q, Xie Z, et al. NDRG4 alleviates Aβ1-40 induction of SH-SY5Y cell injury via activation of BDNF-inducing signalling pathways[J]. Neurochem Res. 2020, 45(7):1492-1499.
|
| 56 |
Huang CC, Chang KH, Chiu YJ, et al. Multi-target effects of novel synthetic coumarin derivatives protecting Aβ-GFP SH-SY5Y cells against Aβ toxicity[J]. Cells, 2021, 10(11):3095. doi: 10.3390/cells10113095.
|
| 57 |
Li F, Wu X, Li J, et al. Ginsenoside Rg1 ameliorates hippocampal long- term potentiation and memory in an Alzheimer's disease model[J]. Mol Med Rep, 2016, 13(6):4904-4910.
|
| 58 |
Lv J, Lu C, Jiang N, et al. Protective effect of ginsenoside Rh2 on scopolamine-induced memory deficits through regulation of cholinergic transmission, oxidative stress and the ERK-CREB-BDNF signaling pathway[J]. Phytother Res, 2021, 35(1):337-345.
|
| 59 |
Yan T, He B, Xu M, et al. Kaempferide prevents cognitive decline via attenuation of oxidative stress and enhancement of brain- derived neurotrophic factor/tropomyosin receptor kinase B/cAMP response element-binding signaling pathway[J]. Phytother Res, 2019, 33(4): 1065-1073.
|
| 60 |
Liu Y, Nguyen M, Robert A, et al. Metal ions in Alzheimer's disease: akey role or not?[J]. Acc Chem Res, 2019, 52(7):2026-2035.
|
| 61 |
Wärmländer S, Österlund N, Wallin C, et al. Metal binding to the amyloid-β peptides in the presence of biomembranes: potential mechanisms of cell toxicity[J]. J Biol Inorg Chem, 2019, 24(8):1189-1196.
|
| 62 |
Duce JA, Bush AI. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics[J]. Prog Neurobiol, 2010, 92(1):1-18.
|
| 63 |
Simunkova M, Alwasel SH, Alhazza IM, et al. Management of oxidative stress and other pathologies in Alzheimer's disease[J]. Arch Toxicol, 2019, 93(9):2491-2513.
|
| 64 |
Poprac P, Jomova K, Simunkova M, et al. Targeting free radicals in oxidative stress-related human diseases[J]. Trends Pharmacol Sci, 2017, 38(7):592-607.
|
| 65 |
Bai R, Guo J, Ye XY, et al. Oxidative stress: the core pathogenesis and mechanism of Alzheimer's disease[J]. Ageing Res Rev, 2022, 77:101619. doi: 10.1016/j.arr.2022.101619.
|
| 66 |
Ma C, Hong F, Yang S. Amyloidosis in Alzheimer's disease: pathogeny, etiology, and related therapeutic directions[J]. Molecules, 2022, 27(4):1210. doi: 10.3390/molecules27041210.
|
| 67 |
Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid[J]. Mol Neurodegener, 2006, 1:5. doi: 10.1186/1750-1326-1-5.
|
| 68 |
Bhattacharyya R, Teves CAF, Long A, et al. The neuronal-specific isoform of BIN1 regulates β-secretase cleavage of APP and Aβ generation in a RIN3-dependent manner[J]. Sci Rep, 2022, 12(1):3486. doi: 10.1038/s41598-022-07372-4.
|
| 69 |
Ulku I, Liebsch F, Akerman SC, et al. Mechanisms of amyloid-β34 generation indicate a pivotal role for BACE1 in amyloid homeostasis[J]. Sci Rep, 2023, 13(1):2216. doi: 10.1038/s41598-023-28846-z.
|
| 70 |
Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein[J]. Biochem Biophys Res Commun, 1984, 120(3):885-890.
|
| 71 |
Hardy JA, Higgins GA. Alzheimer's disease:the amyloid cascade hypothesis[J]. Science, 1992, 256(5054):184-185.
|
| 72 |
Rubin R. Much anticipated Alzheimer disease prevention trial finds no clinical benefit from drug targeting amyloid; highlights need to consider other approaches[J]. Jama, 2022, 328(10):907-910.
|
| 73 |
Hassan W, Noreen H, Rehman S, et al. Association of oxidative stress with neurological disorders[J]. Curr Neuropharmacol, 2022, 20(6): 1046-1072.
|
| 74 |
Steinert JR, Amal H. The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions[J]. Free Radic Biol Med, 2023, 194:71-83.
|
| 75 |
Shadfar S, Parakh S, Jamali MS, et al. Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases[J]. Transl Neurodegener, 2023, 12(1):18. doi: 10.1186/s40035-023-00350-4.
|
| 76 |
Perluigi M, Di Domenico F, Butterfield DA. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease[J]. Physiol Rev, 2024, 104(1):103-197.
|
| 77 |
Wang P, Wang ZY. Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease[J]. Ageing Res Rev, 2017, 35:265-290.
|
| 78 |
Everett J, Lermyte F, Brooks J, et al. Biogenic metallic elements in the human brain?[J]. Sci Adv, 2021, 7(24):eabf6707. doi: 10.1126/sciadv.abf6707.
|
| 79 |
Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zinc in plaques of the swedish mutant beta-amyloid precursor protein transgenic mice[J].J Neurosci, 1999, 19(11):Rc10.
|
| 80 |
Smith MA, Harris PL, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals[J]. Proc Natl Acad Sci U S A, 1997, 94(18):9866-9868.
|
| 81 |
Vejux A. Cell death, inflammation and oxidative stress in neurodegenerative diseases: mechanisms and cytoprotective molecules[J]. Int J Mol Sci, 2021, 22(24):13657. doi: 10.3390/ijms222413657.
|
| 82 |
Devine MJ, Kittler JT. Mitochondria at the neuronal presynapse in health and disease[J]. Nat Rev Neurosci, 2018, 19(2):63-80.
|
| 83 |
Guo L, Tian J, Du H. Mitochondrial dysfunction and synaptic transmission failure in Alzheimer's disease[J]. J Alzheimers Dis, 2017, 57(4):1071-1086.
|
| 84 |
Lee HJ, Jung YH, Choi GE, et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis[J]. Cell Death Differ, 2021, 28(1):184-202.
|
| 85 |
Uttara B, Singh AV, Zamboni P, et al. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options[J]. Curr Neuropharmacol, 2009, 7(1):65-74.
|
| 86 |
Quintana DD, Garcia JA, Anantula Y, et al. Amyloid-β causes mitochondrial dysfunction via a Ca2+-driven upregulation of oxidative phosphorylation and superoxide production in cerebrovascular endothelial cells[J]. J Alzheimers Dis, 2020, 75(1):119-138.
|
| 87 |
Fragoso-Morales LG, Correa-Basurto J, Rosales-Hernández MC. Implication of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and its inhibitors in Alzheimer's disease murine models[J]. Antioxidants (Basel), 2021, 10(2):218. doi: 10.3390/antiox10020218.
|
| 88 |
Ganguly U, Kaur U, Chakrabarti SS, et al. Oxidative stress, neuroinflammation, and NADPH oxidase: implications in the pathogenesis and treatment of Alzheimer's disease[J]. Oxid Med Cell Longev, 2021, 2021:7086512. doi: 10.1155/2021/7086512.
|
| 89 |
Liu Z, Zhou T, Ziegler AC, et al. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications[J]. Oxid Med Cell Longev, 2017, 2017:2525967. doi: 10.1155/2017/2525967.
|
| 90 |
Eckel BD, Cruz R, Jr., Craig EM, et al. Microtubule polarity flaws as a treatable driver of neurodegeneration[J]. Brain Res Bull, 2023, 192:208-215.
|
| 91 |
Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders[J]. Neuromolecular Med, 2002, 2(2):131-150.
|
| 92 |
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease[J]. Mol Neurodegener, 2019, 14(1):32. doi: 10.1186/s13024-019-0333-5.
|
| 93 |
Dumont M, Stack C, Elipenahli C, et al. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice[J]. FASEB J, 2011, 25(11):4063-4072.
|
| 94 |
Gómez-Ramos A, Díaz-Nido J, Smith MA, et al. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells[J]. J Neurosci Res, 2003, 71(6):863-870.
|
| 95 |
Giraldo E, Lloret A, Fuchsberger T, et al. Aβ and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E[J]. Redox Biol, 2014, 2:873-877.
|
| 96 |
Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells[J]. Neurosci Lett, 2010, 468(3):267-271.
|
| 97 |
Stamer K, Vogel R, Thies E, et al. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress[J]. J Cell Biol, 2002, 156(6):1051-1063.
|
| 98 |
Du F, Yu Q, Kanaan NM, et al. Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of Tau oligomers in Alzheimer's disease[J]. Hum Mol Genet, 2022, 31(15):2498-2507.
|
| 99 |
Simpson DSA, Oliver PL. ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease[J]. Antioxidants (Basel), 2020, 9(8):743. doi: 10.3390/antiox9080743.
|
| 100 |
Esteras N, Kundel F, Amodeo GF, et al. Insoluble tau aggregates induce neuronal death through modification of membrane ion conductance, activation of voltage-gated calcium channels and NADPH oxidase[J]. FEBS J, 2021, 288(1):127-141.
|
| 101 |
Ganguly G, Chakrabarti S, Chatterjee U, et al. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease[J]. Drug Des Devel Ther, 2017, 11:797-810.
|
| 102 |
Kandimalla R, Manczak M, Yin X, et al. Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer's disease[J]. Hum Mol Genet, 2018, 27(1):30-40.
|
| 103 |
Althafar ZM. Targeting microglia in Alzheimer's disease: from molecular mechanisms to potential therapeutic targets for small molecules[J]. Molecules, 2022, 27(13):4124. doi: 10.3390/molecules27134124.
|
| 104 |
Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease[J]. J Neuropathol Exp Neurol, 2001, 60(8):759-767.
|
| 105 |
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease[J]. Lancet Neurol, 2015, 14(4):388-405.
|
| 106 |
Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease[J]. Curr Neuropharmacol, 2020, 18(11):1106-1125.
|
| 107 |
Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis[J]. J Neuroinflammation, 2014, 11:48. doi: 10.1186/1742-2094-11-48.
|
| 108 |
Bennett ML, Viaene AN. What are activated and reactive glia and what is their role in neurodegeneration?[J]. Neurobiol Dis, 2021, 148:105172. doi: 10.1016/j.nbd.2020.105172.
|
| 109 |
Hanslik KL, Marino KM, Ulland TK. Modulation of glial function in health, aging, and neurodegenerative disease[J]. Front Cell Neurosci, 2021, 15:718324. doi: 10.3389/fncel.2021.718324.
|
| 110 |
Choi SS, Lee SR, Lee HJ. Neurorestorative role of stem cells in Alzheimer's disease: astrocyte involvement[J]. Curr Alzheimer Res, 2016, 13(4):419-427.
|
| 111 |
Elangovan S, Holsinger RMD. Cyclical amyloid beta-astrocyte activity induces oxidative stress in Alzheimer's disease[J]. Biochimie, 2020, 171-172:38-42.
|
| 112 |
Novoa C, Salazar P, Cisternas P, et al. Inflammation context in Alzheimer's disease, a relationship intricate to define[J]. Biol Res, 2022, 55(1):39. doi: 10.1186/s40659-022-00404-3.
|
| 113 |
Li J, Chen L, Liu S, et al. Hydrocortisone mitigates Alzheimer's-related cognitive decline through modulating oxidative stress and neuroinflammation[J]. Cells, 2023, 12(19):2348. doi: 10.3390/cells12192348.
|
| 114 |
Briggs R, Kennelly SP, O'Neill D. Drug treatments in Alzheimer's disease[J]. Clin Med (Lond), 2016, 16(3):247-253.
|
| 115 |
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease[J]. N Engl J Med, 2023, 388(1):9-21.
|
| 116 |
Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease[J]. Neurotherapeutics, 2023, 20(1):195-206.
|
| 117 |
Friedenstein AJ, Piatetzky S, Ⅱ, Petrakova KV. Osteogenesis in transplants of bone marrow cells[J]. J Embryol Exp Morphol, 1966, 16(3):381-390.
|
| 118 |
Andrzejewska A, Lukomska B, Janowski M. Concise review: mesenchymal stem cells: from roots to boost[J]. Stem Cells, 2019, 37(7):855-864.
|
| 119 |
Uccelli A, Benvenuto F, Laroni A, et al. Neuroprotective features of mesenchymal stem cells[J]. Best Pract Res Clin Haematol, 2011, 24(1):59-64.
|
| 120 |
Babaei H, Kheirollah A, Ranjbaran M, et al. Dose-dependent neuroprotective effects of adipose-derived mesenchymal stem cells on amyloid β-induced Alzheimer's disease in rats[J]. Biochem Biophys Res Commun, 2023, 678:62-67.
|
| 121 |
Kim HJ, Cho KR, Jang H, et al. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial[J]. Alzheimers Res Ther, 2021, 13(1):154. doi: 10.1186/s13195-021-00897-2.
|
| 122 |
Nakano M, Kubota K, Kobayashi E, et al. Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer's disease model by increasing the expression of microRNA-146a in hippocampus[J]. Sci Rep, 2020, 10(1):10772. doi: 10.1038/s41598-020-67460-1.
|
| 123 |
Si Z, Wang X. Stem cell therapies in Alzheimer's disease: applications for disease modeling[J]. J Pharmacol Exp Ther, 2021, 377(2):207-217.
|
| 124 |
Neves AF, Camargo C, Premer C, et al. Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer's disease[J]. Exp Neurol, 2021, 341:113706. doi: 10.1016/j.expneurol.2021.113706.
|
| 125 |
Lee NK, Park SE, Kwon SJ, et al. Agouti related peptide secreted via human mesenchymal stem cells upregulates proteasome activity in an Alzheimer's disease model[J]. Sci Rep, 2017, 7:39340. doi: 10.1038/srep39340.
|
| 126 |
Kim DW, Tu KJ, Wei A, et al. Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes[J]. Mol Neurodegener, 2022, 17(1):83. doi: 10.1186/s13024-022-00589-x.
|
| 127 |
Razavi S, Razavi MR, Zarkesh Esfahani H, et al. Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells[J]. Dev Growth Differ, 2013, 55(6):648-655.
|
| 128 |
Song MS, Learman CR, Ahn KC, et al. In vitro validation of effects of BDNF-expressing mesenchymal stem cells on neurodegeneration in primary cultured neurons of APP/PS1 mice[J]. Neuroscience, 2015, 307:37-50.
|
| 129 |
Kaniowska D, Wenk K, Rademacher P, et al. Extracellular vesicles of mesenchymal stromal cells can be taken up by microglial cells and partially prevent the stimulation induced by β-amyloid[J]. Stem Cell Rev Rep, 2022, 18(3):1113-1126.
|
| 130 |
Hasanpour M, Rahbarghazi R, Nourazarian A, et al. Conditioned medium from amniotic fluid mesenchymal stem cells could modulate Alzheimer's disease-like changes in human neuroblastoma cell line SY-SY5Y in a paracrine manner[J]. Tissue Cell, 2022, 76:101808. doi: 10.1016/j.tice.2022.101808.
|
| 131 |
Yokokawa K, Iwahara N, Hisahara S, et al. Transplantation of mesenchymal stem cells improves amyloid-β pathology by modifying microglial function and suppressing oxidative stress[J]. J Alzheimers Dis, 2019, 72(3):867-884.
|
| 132 |
Regmi S, Liu DD, Shen M, et al. Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations[J]. Front Mol Neurosci, 2022, 15:1011225.
|
| 133 |
Zhan J, Li X, Luo D, et al. Polydatin promotes the neuronal differentiation of bone marrow mesenchymal stem cells in vitro and in vivo: Involvement of Nrf2 signalling pathway[J]. J Cell Mol Med, 2020, 24(9):5317-5329.
|
| 134 |
Jang S, Kang YH, Ullah I, et al. Cholinergic nerve differentiation of mesenchymal stem cells derived from long-term cryopreserved human dental pulp in vitro and analysis of their motor nerve regeneration potential in vivo[J]. Int J Mol Sci, 2018, 19(8):2434. doi: 10.3390/ijms19082434.
|
| 135 |
de Godoy MA, Saraiva LM, de Carvalho LRP, et al. Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers[J]. J Biol Chem, 2018, 293(6):1957-1975.
|
| 136 |
Bodart-Santos V, de Carvalho LRP, de Godoy MA, et al. Extracellular vesicles derived from human Wharton's jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers[J]. Stem Cell Res Ther, 2019, 10(1):332. doi: 10.1186/s13287-019-1432-5.
|
| 137 |
Wen C, Huang C, Yang M, et al. The secretion from bone marrow mesenchymal stem cells pretreated with berberine rescues neurons with oxidative damage through activation of the Keap1-Nrf2-HO-1 signaling pathway[J]. Neurotox Res, 2020, 38(1):59-73.
|
| 138 |
Lee HJ, Lee JK, Lee H, et al. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease[J]. Neurosci Lett, 2010, 481(1):30-35.
|
| 139 |
Yang H, Yue C, Yang H, et al. Intravenous administration of human umbilical cord mesenchymal stem cells improves cognitive impairments and reduces amyloid-beta deposition in an AβPP/PS1 transgenic mouse model[J]. Neurochem Res, 2013.doi: 10.1007/s11064-013-1161-6.
|
| 140 |
Aragón-González A, Shaw PJ, Ferraiuolo L. Blood-brain barrier disruption and its involvement in neurodevelopmental and neurodegenerative disorders[J]. Int J Mol Sci, 2022, 23(23):15271. doi: 10.3390/ijms232315271.
|
| 141 |
Alkhalifa AE, Al-Ghraiybah NF, Odum J, et al. Blood-brain barrier breakdown in Alzheimer's disease: mechanisms and targeted strategies[J]. Int J Mol Sci, 2023, 24(22):16288. doi: 10.3390/ijms242216288.
|
| 142 |
Seo BM, Miura M, Sonoyama W, et al. Recovery of stem cells from cryopreserved periodontal ligament[J]. J Dent Res, 2005, 84(10):907-912.
|
| 143 |
Luo L, He Y, Wang X, et al. Potential roles of dental pulp stem cells in neural regeneration and repair[J]. Stem Cells Int, 2018, 2018:1731289. doi: 10.1155/2018/1731289.
|
| 144 |
Honda M, Ohshima H. Biological characteristics of dental pulp stem cells and their potential use in regenerative medicine[J]. J Oral Biosci, 2022, 64(1):26-36.
|
| 145 |
Goorha S, Victor AK, Reiter LT. Culturing and neuronal differentiation of human dental pulp stem cells[J]. Curr Protoc, 2022, 2(11):e600. doi: 10.1002/cpz1.600.
|
| 146 |
Ahmed Nel M, Murakami M, Hirose Y, et al. Therapeutic potential of dental pulp stem cell secretome for Alzheimer's disease treatment: an in vitro study[J]. Stem Cells Int, 2016, 2016:8102478. doi: 10.1155/2016/8102478.
|
| 147 |
Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role[J]. Neurobiol Aging, 2010, 31(1):8-16.
|
| 148 |
Religa P, Cao R, Religa D, et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival[J]. Sci Rep, 2013, 3:2053. doi: 10.1038/srep02053.
|
| 149 |
Sanchez-Sanchez JL, Giudici KV, Guyonnet S, et al. Plasma MCP- 1 and changes on cognitive function in community-dwelling older adults[J]. Alzheimers Res Ther, 2022, 14(1):5. doi: 10.1186/s13195-021-00940-2.
|
| 150 |
Eugenín J, Eugenín-von Bernhardi L, von Bernhardi R. Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases[J]. Front Mol Neurosci, 2023, 16:1249320. doi: 10.3389/fnmol.2023.1249320.
|
| 151 |
Panyard DJ, McKetney J, Deming YK, et al. Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease[J]. Alzheimers Dement, 2023, 19(12):5447-5470.
|
| 152 |
Boyd TD, Bennett SP, Mori T, et al. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice[J]. J Alzheimers Dis, 2010, 21(2):507-18.
|
| 153 |
Wang F, Jia Y, Liu J, et al. Dental pulp stem cells promote regeneration of damaged neuron cells on the cellular model of Alzheimer's disease[J]. Cell Biol Int, 2017, 41(6):639-650.
|
| 154 |
Mishra M, Raik S, Rattan V, et al. Mitochondria transfer as a potential therapeutic mechanism in Alzheimer's disease-like pathology[J]. Brain Res, 2023, 1819:148544. doi: 10.1016/j.brainres.2023.148544.
|
| 155 |
Howlader MSI, Prateeksha P, Hansda S, et al. Secretory products of DPSC mitigate inflammatory effects in microglial cells by targeting MAPK pathway[J]. Pharmacother, 2024, 170:115971. doi: 10.1016/j.biopha.2023.115971.
|
| 156 |
Venugopal C, Shobha K, Rai KS, et al. Neurogenic and cognitive enhancing effects of human dental pulp stem cells and its secretome in animal model of hippocampal neurodegeneration[J]. Brain Res Bull, 2022, 180:46-58.
|
| 157 |
Mita T, Furukawa-Hibi Y, Takeuchi H, et al. Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer's disease[J]. Behav Brain Res, 2015, 293:189-197.
|
| 158 |
赵志英,胡海涛,冯改丰,等.人脑源性神经营养因子基因修饰神经干细胞移植对痴呆大鼠学习记忆的改善[J].中国修复重建外科杂志, 2005, 19(5):331-334.
|
| 159 |
Hu W, Feng Z, Xu J, et al. Brain-derived neurotrophic factor modified human umbilical cord mesenchymal stem cells-derived cholinergic-like neurons improve spatial learning and memory ability in Alzheimer's disease rats[J]. Brain Res, 2019, 1710:61-73.
|
| 160 |
Wihadmadyatami H, Zulfikar MA, Herawati H, et al. Chitosan hydrogel nanoparticle enhance therapeutic effect of bovine umbilical mesenchymal stem cell conditioned medium on canine cognitive dysfunction or canine Alzheimer's like mediated by inhibition of neuronal apoptotic[J]. Open Vet J, 2023, 13(12):1504-1516.
|
| 161 |
Pollock K, Dahlenburg H, Nelson H, et al. Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington's disease mouse models[J]. Mol Ther, 2016, 24(5):965-977.
|